Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Sexual Dysfunction, Physiological × Estradiol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Polycystic Ovary Syndrome 10 Osteoporosis 2 Neoplasm Metastasis 2 Vaginitis 1 Triple Negative Breast Neoplasms 1 Sexual Dysfunction, Physiological 1 Prostatic Neoplasms 1 Neoplasms 1 Infertility, Female 1 Infertility 1 Hyperandrogenism 1 Hot Flashes 1 Estrogen Receptor Positive Breast Cancer 1 Estrogen Levels Among Breast Cancer Patients 1 Coronary Disease 1 Cardiovascular Diseases 1 Atrophic Vaginitis 1 Anemia 1 Anatomic Stage III Breast Cancer AJCC v8 1 Abortion, Spontaneous 1

Interventions

Surveys and Questionnaires 5 Therapeutics 2 Radiotherapy 2 Psychiatric Rehabilitation 2 Exercise 2 trametinib 1 sotorasib 1 selpercatinib 1 pembrolizumab 1 osimertinib 1 methyl 3-mercaptopropionimidate 1 lorlatinib 1 dabrafenib 1 cemiplimab 1 brigatinib 1 bicalutamide 1 alectinib 1 Vitamin E 1 Uterine Myomectomy 1 Testosterone Propionate 1 Testosterone 1 Sexual Health 1 Sex Education 1 Restraint, Physical 1 Radiosurgery 1 Quality of Life 1 Pilocarpine 1 Pemetrexed 1 Paclitaxel 1 Nutrition Assessment 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00698035 2014-06-02

E-String

University of California, San Francisco

Phase 2 Completed

76 enrolled 11 charts

Sexual Dysfunction, Physiological

Data powered by HemOnc (CC BY 4.0) Colophon ⚡